PortalPublikationenAnalysis of testosterone suppression in men receiving histre...

Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.

Standard

Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. / Bob, Djavan; Schlegel, Peter; Salomon, Georg; Eckersberger, Elisabeth; Sadri, Helen; Graefen, Markus.

in: CAN J UROL, Jahrgang 17, Nr. 4, 4, 2010, S. 5265-5271.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bob, D, Schlegel, P, Salomon, G, Eckersberger, E, Sadri, H & Graefen, M 2010, 'Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.', CAN J UROL, Jg. 17, Nr. 4, 4, S. 5265-5271. <http://www.ncbi.nlm.nih.gov/pubmed/20735905?dopt=Citation>

APA

Bob, D., Schlegel, P., Salomon, G., Eckersberger, E., Sadri, H., & Graefen, M. (2010). Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. CAN J UROL, 17(4), 5265-5271. [4]. http://www.ncbi.nlm.nih.gov/pubmed/20735905?dopt=Citation

Vancouver

Bob D, Schlegel P, Salomon G, Eckersberger E, Sadri H, Graefen M. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. CAN J UROL. 2010;17(4):5265-5271. 4.

Bibtex

@article{343b81662c924629aede322cee358da2,
title = "Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.",
abstract = "Androgen deprivation therapy (ADT) is the standard care in men with advanced prostate cancer. Continuous testosterone suppression is essential to treatment efficacy. Recently a 1 year depot compound, histrelin, (VANTAS: Orion Pharmaceuticals, Finland; Endo Pharmaceuticals, USA), a gonadotropin-releasing hormone (GnRH) analog, was approved for hormone therapy of prostate cancer. In the present study the therapeutic efficacy of this compound was investigated, in addition to its impact on testosterone values and velocity as well as PSA.",
author = "Djavan Bob and Peter Schlegel and Georg Salomon and Elisabeth Eckersberger and Helen Sadri and Markus Graefen",
year = "2010",
language = "Deutsch",
volume = "17",
pages = "5265--5271",
journal = "CAN J UROL",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "4",

}

RIS

TY - JOUR

T1 - Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.

AU - Bob, Djavan

AU - Schlegel, Peter

AU - Salomon, Georg

AU - Eckersberger, Elisabeth

AU - Sadri, Helen

AU - Graefen, Markus

PY - 2010

Y1 - 2010

N2 - Androgen deprivation therapy (ADT) is the standard care in men with advanced prostate cancer. Continuous testosterone suppression is essential to treatment efficacy. Recently a 1 year depot compound, histrelin, (VANTAS: Orion Pharmaceuticals, Finland; Endo Pharmaceuticals, USA), a gonadotropin-releasing hormone (GnRH) analog, was approved for hormone therapy of prostate cancer. In the present study the therapeutic efficacy of this compound was investigated, in addition to its impact on testosterone values and velocity as well as PSA.

AB - Androgen deprivation therapy (ADT) is the standard care in men with advanced prostate cancer. Continuous testosterone suppression is essential to treatment efficacy. Recently a 1 year depot compound, histrelin, (VANTAS: Orion Pharmaceuticals, Finland; Endo Pharmaceuticals, USA), a gonadotropin-releasing hormone (GnRH) analog, was approved for hormone therapy of prostate cancer. In the present study the therapeutic efficacy of this compound was investigated, in addition to its impact on testosterone values and velocity as well as PSA.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 5265

EP - 5271

JO - CAN J UROL

JF - CAN J UROL

SN - 1195-9479

IS - 4

M1 - 4

ER -